In conclusion, our findings provide support for both NGS and IdyllaTM assays to be adopted as the molecular method of choice for routine assessment of BRAF status in MM patients and to provide guidance toward the appropriate treatment strategy. This evidence concerns the gene BRAF and Miyoshi myopathy.